Q3 2018 13F Holders as of 30 Sep 2018
-
Type / Class
-
Debt / NOTE 3.250%11/0
-
Market price (% of par)
-
118.25%
-
Total 13F principal
-
$223,483,000
-
Principal change
-
-$6,725,000
-
Total reported market value
-
$263,688,000
-
Number of holders
-
19
-
Value change
-
-$5,951,946
-
Number of buys
-
3
-
Number of sells
-
5
Institutional Holders of THERAVANCE BIOPHARMA INC - NOTE 3.250%11/0 as of Q3 2018
As of 30 Sep 2018,
THERAVANCE BIOPHARMA INC - NOTE 3.250%11/0 was held by
19 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$223,483,000
in principal (par value) of the bond.
The largest 10 bondholders included
Linden Advisors LP, BAUPOST GROUP LLC/MA, CITADEL ADVISORS LLC, WOLVERINE ASSET MANAGEMENT LLC, ZAZOVE ASSOCIATES LLC, Castle Creek Arbitrage, LLC, Context Partners Fund, L.P., Context Capital Management, LLC, Verition Fund Management LLC, and FMR LLC.
This page lists
19
institutional bondholders reporting positions
for the Q3 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.